Shahla Shahbazi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shahla Shahbazi has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Samira Sabzi
Medical Microbiology Research Center Qazvin University of Medical Sciences Qazvin Iran
6 shared publications - Mehri Habibi
Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran
3 shared publications - Mohammad Reza Asadi Karam
Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran
3 shared publications - Farzad Badmasti
Department of Bacteriology, Pasteur Institute of Iran, Tehran, Iran
2 shared publications - Keyghobad Ghadiri
Infectious Diseases Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
2 shared publications - Majid Taati Moghadam
Department of Microbiology, Virology and Microbial Toxins, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
2 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Taylor & Francis in HIV/AIDS - Research and Palliative Care
- Vol. ume 18, 1-11
Factors Affecting Changes in CD4+ T-cell Count Among People Living with HIV (PLWH): A Retrospective Cohort Study in Kermanshah, Iran
Background and Objective: Considering the crucial role of CD4+ T-cell counts in disease control and management, the present study aimed to investigate changes in CD4+ T-cell counts among People Living with HIV (PLWH) at the Behavioral Diseases Counseling Center in Kermanshah Province. The study also assessed the impact of demographic and clinical factors, including age, gender, duration of infection, duration of antiretroviral therapy (ART), and CD4+ T-cell count, on changes in CD4+ T-cell counts during ART among PLWH. Methods: In this retrospective study, the medical records of 2909 PLWH who had attended the Kermanshah Behavioral Diseases Counseling Center between 2012 and 2023 were reviewed. Demographic, behavioral, and clinical data were extracted from the records. Ultimately, 728 individuals whose CD4+ T-cell counts were documented both at diagnosis and after treatment were included in the analysis. Data were analyzed using SPSS version 21. As CD4+ T- cell count changes were not normally distributed, robust linear regression was employed. Collinearity among independent variables and autocorrelation of errors were assessed and confirmed. The assumption of homoscedasticity of errors was also evaluated and satisfied. Results: Among the 728 PLWH, 519 (71.3%) were male and 209 (28.7%) were female. The mean age of the PLWH was 37.2 ± 11.5 years. The mean CD4+ T-cell count at diagnosis was 336.4 cells/μL, which increased to 526.4 cells/μL after treatment. The average duration of treatment was 57.8 months (SD = 34.5), and the average number of follow-up visits was 48.6 (SD = 36.9). Robust linear regression, with ART duration entered as a four-level category, showed that longer ART duration (1– 5 years: B=111.9; 5– 10 years: B=267.5; > 10 years: B=527.3, all vs < 1 year, p< 0.001), higher education (B=302.6, 95% CI: 171.5– 433.7), older age (B=5.3, 95% CI: 2.4– 8.3), and sexual transmission (B=101.6, 95% CI: 18.0– 185.2) were significantly associated with improved CD4+ T-cell recovery (p< 0.05). Female sex, more advanced clinical stage (III–IV), and certain occupational categories were also significantly associated with CD4+ T-cell recovery, while a longer duration of infection was associated with lower CD4+ T-cell recovery (all p< 0.05). Conclusion: Consistent with the well-established effect of antiretroviral therapy on CD4+ T-cell recovery, this study suggests that immune recovery is influenced by both treatment duration and patients’ demographic and clinical characteristics. These findings emphasize the importance of individualized HIV care, with closer monitoring and adherence support for patients at risk of poorer immune recovery.
- 1 September 2026
- Published by Taylor & Francis in HIV/AIDS - Research and Palliative Care
- Vol. ume 18, 1-11
Open AccessFactors Affecting Changes in CD4+ T-cell Count Among People Living with HIV (PLWH): A Retrospective Cohort Study in Kermanshah, Iran
Background and Objective: Considering the crucial role of CD4+ T-cell counts in disease control and management, the present study aimed to investigate changes in CD4+ T-cell counts among People Living with HIV (PLWH) at the Behavioral Diseases Counseling Center in Kermanshah Province. The study also assessed the impact of demographic and clinical factors, including age, gender, duration of infection, duration of antiretroviral therapy (ART), and CD4+ T-cell count, on changes in CD4+ T-cell counts during ART among PLWH. Methods: In this retrospective study, the medical records of 2909 PLWH who had attended the Kermanshah Behavioral Diseases Counseling Center between 2012 and 2023 were reviewed. Demographic, behavioral, and clinical data were extracted from the records. Ultimately, 728 individuals whose CD4+ T-cell counts were documented both at diagnosis and after treatment were included in the analysis. Data were analyzed using SPSS version 21. As CD4+ T- cell count changes were not normally distributed, robust linear regression was employed. Collinearity among independent variables and autocorrelation of errors were assessed and confirmed. The assumption of homoscedasticity of errors was also evaluated and satisfied. Results: Among the 728 PLWH, 519 (71.3%) were male and 209 (28.7%) were female. The mean age of the PLWH was 37.2 ± 11.5 years. The mean CD4+ T-cell count at diagnosis was 336.4 cells/μL, which increased to 526.4 cells/μL after treatment. The average duration of treatment was 57.8 months (SD = 34.5), and the average number of follow-up visits was 48.6 (SD = 36.9). Robust linear regression, with ART duration entered as a four-level category, showed that longer ART duration (1– 5 years: B=111.9; 5– 10 years: B=267.5; > 10 years: B=527.3, all vs < 1 year, p< 0.001), higher education (B=302.6, 95% CI: 171.5– 433.7), older age (B=5.3, 95% CI: 2.4– 8.3), and sexual transmission (B=101.6, 95% CI: 18.0– 185.2) were significantly associated with improved CD4+ T-cell recovery (p< 0.05). Female sex, more advanced clinical stage (III–IV), and certain occupational categories were also significantly associated with CD4+ T-cell recovery, while a longer duration of infection was associated with lower CD4+ T-cell recovery (all p< 0.05). Conclusion: Consistent with the well-established effect of antiretroviral therapy on CD4+ T-cell recovery, this study suggests that immune recovery is influenced by both treatment duration and patients’ demographic and clinical characteristics. These findings emphasize the importance of individualized HIV care, with closer monitoring and adherence support for patients at risk of poorer immune recovery.
- Open Access
- 19 August 2026
- Published by Wiley in Microbiologyopen
- Vol. 15 (4) , e70378
Green‐Synthesized Silver Nanoparticles Against Acinetobacter baumannii : A Systematic Review of Antibacterial Activity, Mechanisms of Action, Toxicity, and Antibiofilm Effects
Acinetobacter baumannii is a major multidrug‐resistant nosocomial pathogen, and new antimicrobial strategies are urgently needed. Green‐synthesized silver nanoparticles (AgNPs) have emerged as promising candidates because of their broad antibacterial activity and potentially improved biocompatibility. This systematic review evaluated the antibacterial effects of pure, plant‐mediated AgNPs against A. baumannii isolates. PubMed, Scopus, and Web of Science were searched from database inception to October 5, 2025 according to PRISMA guidelines. Eligible studies were original English‐language reports assessing pure green‐synthesized AgNPs against A. baumannii . Sixty‐three studies met the inclusion criteria. Green AgNPs were generally active against A. baumannii and more often showed stronger effects than the corresponding plant extracts. The most commonly proposed mechanisms were reactive oxygen species generation, membrane and cell–wall disruption, increased permeability, and damage to proteins, lipids, or DNA. Biofilm data were limited but suggested promising inhibitory potential. Toxicity findings were mixed, ranging from good biocompatibility to cytotoxicity in sensitive cell models. Plant‐mediated AgNPs show credible antibacterial potential against A. baumannii , but standardized synthesis, rigorous characterization, biofilm‐focused testing, and in vivo safety studies are still needed before clinical translation.
- 19 August 2026
- Published by Wiley in Microbiologyopen
- Vol. 15 (4) , e70378
Open AccessGreen‐Synthesized Silver Nanoparticles Against Acinetobacter baumannii : A Systematic Review of Antibacterial Activity, Mechanisms of Action, Toxicity, and Antibiofilm Effects
Acinetobacter baumannii is a major multidrug‐resistant nosocomial pathogen, and new antimicrobial strategies are urgently needed. Green‐synthesized silver nanoparticles (AgNPs) have emerged as promising candidates because of their broad antibacterial activity and potentially improved biocompatibility. This systematic review evaluated the antibacterial effects of pure, plant‐mediated AgNPs against A. baumannii isolates. PubMed, Scopus, and Web of Science were searched from database inception to October 5, 2025 according to PRISMA guidelines. Eligible studies were original English‐language reports assessing pure green‐synthesized AgNPs against A. baumannii . Sixty‐three studies met the inclusion criteria. Green AgNPs were generally active against A. baumannii and more often showed stronger effects than the corresponding plant extracts. The most commonly proposed mechanisms were reactive oxygen species generation, membrane and cell–wall disruption, increased permeability, and damage to proteins, lipids, or DNA. Biofilm data were limited but suggested promising inhibitory potential. Toxicity findings were mixed, ranging from good biocompatibility to cytotoxicity in sensitive cell models. Plant‐mediated AgNPs show credible antibacterial potential against A. baumannii , but standardized synthesis, rigorous characterization, biofilm‐focused testing, and in vivo safety studies are still needed before clinical translation.
- Open Access
- 1 January 2026
- Published by Wiley in BioMed Research International
- Vol. 2026 (1) , 7584584
Insights Into Infections and Inflammation in Prostate Cancer Development and Management: An Overview
Prostate cancer (PCa) represents a major public health concern and continues to be one of the leading causes of cancer‐related mortality among men worldwide. Current epidemiological projections suggest that the incidence and associated burden of PCa are likely to increase, emphasizing the importance of advancing preventive measures, improving early diagnostic approaches, and refining targeted therapeutic strategies. While established risk factors, including age, genetic predisposition, lifestyle‐related factors, ethnicity, and androgen signaling, have been extensively studied, these factors alone do not fully explain the observed patterns of PCa development. Increasing evidence suggests that infection‐associated chronic inflammation plays a central role in prostate tumor initiation and progression. Chronic inflammation of the prostate, arising from conditions such as prostatitis, benign prostatic hyperplasia (BPH), lower urinary tract infections (UTIs), sexually transmitted infections (STIs), and prolonged or repeated catheterization, has been associated with histological and molecular changes that may predispose prostate tissue to malignant transformation. Moreover, emerging evidence suggests that alterations in the prostate microbiome may sustain inflammatory signaling, thereby influencing tumor initiation and progression. This review synthesizes current epidemiological findings and experimental evidence linking infection‐associated inflammation to the development of PCa. Particular focus is placed on inflammatory signaling pathways implicated in prostate tumorigenesis, including nuclear factor kappa B (NF‐ κ B), signal transducer and activator of transcription 3 (STAT3), cyclooxygenase‐2/prostaglandin E 2 (COX‐2/PGE 2 ), interleukin‐6 and interleukin‐8 signaling, Toll‐like receptor (TLR) pathways, and activation of the NLRP3 inflammasome. In addition, we discuss therapeutic strategies that are aimed at modulating these pathways and their potential relevance in PCa management. A more comprehensive understanding of the interactions between infection, chronic inflammation, and PCa development may facilitate the identification of novel biomarkers and therapeutic targets. Such advances could ultimately contribute to improved risk stratification, earlier detection, and more effective treatment of PCa.
- 1 January 2026
- Published by Wiley in BioMed Research International
- Vol. 2026 (1) , 7584584
Open AccessInsights Into Infections and Inflammation in Prostate Cancer Development and Management: An Overview
Prostate cancer (PCa) represents a major public health concern and continues to be one of the leading causes of cancer‐related mortality among men worldwide. Current epidemiological projections suggest that the incidence and associated burden of PCa are likely to increase, emphasizing the importance of advancing preventive measures, improving early diagnostic approaches, and refining targeted therapeutic strategies. While established risk factors, including age, genetic predisposition, lifestyle‐related factors, ethnicity, and androgen signaling, have been extensively studied, these factors alone do not fully explain the observed patterns of PCa development. Increasing evidence suggests that infection‐associated chronic inflammation plays a central role in prostate tumor initiation and progression. Chronic inflammation of the prostate, arising from conditions such as prostatitis, benign prostatic hyperplasia (BPH), lower urinary tract infections (UTIs), sexually transmitted infections (STIs), and prolonged or repeated catheterization, has been associated with histological and molecular changes that may predispose prostate tissue to malignant transformation. Moreover, emerging evidence suggests that alterations in the prostate microbiome may sustain inflammatory signaling, thereby influencing tumor initiation and progression. This review synthesizes current epidemiological findings and experimental evidence linking infection‐associated inflammation to the development of PCa. Particular focus is placed on inflammatory signaling pathways implicated in prostate tumorigenesis, including nuclear factor kappa B (NF‐ κ B), signal transducer and activator of transcription 3 (STAT3), cyclooxygenase‐2/prostaglandin E 2 (COX‐2/PGE 2 ), interleukin‐6 and interleukin‐8 signaling, Toll‐like receptor (TLR) pathways, and activation of the NLRP3 inflammasome. In addition, we discuss therapeutic strategies that are aimed at modulating these pathways and their potential relevance in PCa management. A more comprehensive understanding of the interactions between infection, chronic inflammation, and PCa development may facilitate the identification of novel biomarkers and therapeutic targets. Such advances could ultimately contribute to improved risk stratification, earlier detection, and more effective treatment of PCa.
- 22 July 2025
- Published by Wiley in Journal of Basic Microbiology
- Vol. 65 (11) , e70078
Engineered Phages and Engineered and Recombinant Endolysins Against Carbapenem‐Resistant Gram‐Negative Bacteria: A Focused Review on Novel Antibacterial Strategies
Antibiotic resistance has escalated globally, affecting not only commonly used antibiotics but also last‐resort agents such as carbapenems and colistin. The rise of antibiotic‐resistant bacteria has prompted microbiologists to devise new strategies, with bacteriophages emerging as one of the most promising options. Nevertheless, certain mechanisms have been identified in bacteria that confer resistance to phages. While phage resistance is currently less widespread than antibiotic resistance, challenges such as biofilm formation, newly emerging resistance mechanisms against phages, and the natural limitations of unmodified phages have driven the advancement of engineered phages. This study aims to examine the efficacy of engineered phages and both engineered and recombinant endolysins against carbapenem‐resistant Gram‐negative bacteria (CR‐GNB). We performed a literature review through PubMed, Scopus, Web of Science, and Google Scholar, concentrating on studies that utilized these agents against carbapenem‐resistant Gram‐negative bacteria (CR‐GNB). Reviewed studies indicate potential antibacterial activity of these agents against CR‐GNB. By engineering and modifying phages, these agents exhibit improved antimicrobial efficacy, temperature stability, and membrane permeability. Furthermore, they demonstrate the ability to eliminate bacteria with multidrug‐resistant (MDR) and extensively drug‐resistant (XDR) profiles. These findings suggest the promising potential of engineered phages and endolysins for future clinical applications against CR‐GNB.
- 22 July 2025
- Published by Wiley in Journal of Basic Microbiology
- Vol. 65 (11) , e70078
Engineered Phages and Engineered and Recombinant Endolysins Against Carbapenem‐Resistant Gram‐Negative Bacteria: A Focused Review on Novel Antibacterial Strategies
Antibiotic resistance has escalated globally, affecting not only commonly used antibiotics but also last‐resort agents such as carbapenems and colistin. The rise of antibiotic‐resistant bacteria has prompted microbiologists to devise new strategies, with bacteriophages emerging as one of the most promising options. Nevertheless, certain mechanisms have been identified in bacteria that confer resistance to phages. While phage resistance is currently less widespread than antibiotic resistance, challenges such as biofilm formation, newly emerging resistance mechanisms against phages, and the natural limitations of unmodified phages have driven the advancement of engineered phages. This study aims to examine the efficacy of engineered phages and both engineered and recombinant endolysins against carbapenem‐resistant Gram‐negative bacteria (CR‐GNB). We performed a literature review through PubMed, Scopus, Web of Science, and Google Scholar, concentrating on studies that utilized these agents against carbapenem‐resistant Gram‐negative bacteria (CR‐GNB). Reviewed studies indicate potential antibacterial activity of these agents against CR‐GNB. By engineering and modifying phages, these agents exhibit improved antimicrobial efficacy, temperature stability, and membrane permeability. Furthermore, they demonstrate the ability to eliminate bacteria with multidrug‐resistant (MDR) and extensively drug‐resistant (XDR) profiles. These findings suggest the promising potential of engineered phages and endolysins for future clinical applications against CR‐GNB.
- Open Access
Phage and Endolysin Therapy Against Antibiotics Resistant Bacteria: From Bench to Bedside
The rapid global spread of antibiotic‐resistant bacteria presents a growing public health crisis, threatening the efficacy of existing antimicrobial treatments. As traditional antibiotics become increasingly ineffective, alternative therapies such as bacteriophages and endolysins have gained renewed scientific and clinical interest. These biological agents, naturally derived from bacteriophage life cycles, exhibit potent and selective antibacterial activity, especially against multidrug‐resistant pathogens. Despite decades of research, the clinical translation of phage and endolysin therapies remains limited due to regulatory, delivery, and stability challenges. This review provides a comprehensive overview of the mechanisms, advantages, and limitations of both bacteriophages and endolysins, including their structure, mode of action, and interaction with bacterial hosts. Particular attention is given to combination therapies, where synergistic effects have been observed–especially in biofilm‐associated infections. We also explore the latest findings from preclinical studies, clinical trials, and compassionate‐use cases, with an emphasis on genetically engineered and synthetic variants that enhance therapeutic potential. Furthermore, we discuss manufacturing challenges, regulatory barriers, and future directions such as personalized phage therapy and engineered endolysins. By synthesizing current knowledge, this review highlights the academic and translational significance of phage and endolysin‐based approaches in combating antibiotic‐resistant infections.
Open AccessPhage and Endolysin Therapy Against Antibiotics Resistant Bacteria: From Bench to Bedside
The rapid global spread of antibiotic‐resistant bacteria presents a growing public health crisis, threatening the efficacy of existing antimicrobial treatments. As traditional antibiotics become increasingly ineffective, alternative therapies such as bacteriophages and endolysins have gained renewed scientific and clinical interest. These biological agents, naturally derived from bacteriophage life cycles, exhibit potent and selective antibacterial activity, especially against multidrug‐resistant pathogens. Despite decades of research, the clinical translation of phage and endolysin therapies remains limited due to regulatory, delivery, and stability challenges. This review provides a comprehensive overview of the mechanisms, advantages, and limitations of both bacteriophages and endolysins, including their structure, mode of action, and interaction with bacterial hosts. Particular attention is given to combination therapies, where synergistic effects have been observed–especially in biofilm‐associated infections. We also explore the latest findings from preclinical studies, clinical trials, and compassionate‐use cases, with an emphasis on genetically engineered and synthetic variants that enhance therapeutic potential. Furthermore, we discuss manufacturing challenges, regulatory barriers, and future directions such as personalized phage therapy and engineered endolysins. By synthesizing current knowledge, this review highlights the academic and translational significance of phage and endolysin‐based approaches in combating antibiotic‐resistant infections.
- Open Access
- 1 July 2024
- Published by Apex Publishing in Iranian Biomedical Journal
- Vol. 28 (4) , 156-167
In silico and in vivo Investigations of the Immunoreactivity of Klebsiella pneumoniae OmpA Protein as a Vaccine Candidate
Background: The growing threat of antibiotic resistance and Klebsiella pneumoniae infection in healthcare settings highlights the urgent need for innovative solutions, such as vaccines, to address these challenges. This study sought to assess the potential of using K. pneumoniae outer membrane protein A (OmpA) as a vaccine candidate through both in silico ...
- 1 July 2024
- Published by Apex Publishing in Iranian Biomedical Journal
- Vol. 28 (4) , 156-167
Open AccessIn silico and in vivo Investigations of the Immunoreactivity of Klebsiella pneumoniae OmpA Protein as a Vaccine Candidate
Background: The growing threat of antibiotic resistance and Klebsiella pneumoniae infection in healthcare settings highlights the urgent need for innovative solutions, such as vaccines, to address these challenges. This study sought to assess the potential of using K. pneumoniae outer membrane protein A (OmpA) as a vaccine candidate through both in silico ...
- Open Access
- 1 April 2024
- Published by Elsevier in New Microbes and New Infections
- Vol. 59, 101275
Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- 1 April 2024
- Published by Elsevier in New Microbes and New Infections
- Vol. 59, 101275
Open AccessUpregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- 8 November 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 125 (Pt B) , 111171
Design and fabrication of a vaccine candidate based on rOmpA from Klebsiella pneumoniae encapsulated in silk fibroin-sodium alginate nanoparticles against pneumonia infection
- 8 November 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 125 (Pt B) , 111171
Design and fabrication of a vaccine candidate based on rOmpA from Klebsiella pneumoniae encapsulated in silk fibroin-sodium alginate nanoparticles against pneumonia infection
- 26 October 2023
- Published by Taylor & Francis in Future Microbiology
- Vol. 18 (16) , 1171-1183
Antibiotic Resistance and Genetic Diversity Among Pseudomonas Aeruginosa Isolated from Urinary Tract Infections in Iran
Aims: To determine the antibiotic resistance and genetic diversity of Pseudomonas aeruginosa isolates. Methods: The antibiotic resistance, genetic diversity and the conjugate transformation among P...
- 26 October 2023
- Published by Taylor & Francis in Future Microbiology
- Vol. 18 (16) , 1171-1183
Antibiotic Resistance and Genetic Diversity Among Pseudomonas Aeruginosa Isolated from Urinary Tract Infections in Iran
Aims: To determine the antibiotic resistance and genetic diversity of Pseudomonas aeruginosa isolates. Methods: The antibiotic resistance, genetic diversity and the conjugate transformation among P...
- 26 October 2023
- Published by Taylor & Francis in Future Microbiology
- Vol. 18 (18) , 1353-1361
Molecular Study on Virulence and Resistance Genes of ST131 Clone (Uropathogenic/Enteropathogenic Escherichia Coli ) Hybrids in Children
Aim: To analyze ST131 clones and other characteristics in uropathogenic and atypical enteropathogenic Escherichia coli hybrids. Methods: Samples were collected from children with urinary tract infe...
- 26 October 2023
- Published by Taylor & Francis in Future Microbiology
- Vol. 18 (18) , 1353-1361
Molecular Study on Virulence and Resistance Genes of ST131 Clone (Uropathogenic/Enteropathogenic Escherichia Coli ) Hybrids in Children
Aim: To analyze ST131 clones and other characteristics in uropathogenic and atypical enteropathogenic Escherichia coli hybrids. Methods: Samples were collected from children with urinary tract infe...